| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111
Fibroblast activation protein (FAP) is a type II integral membrane glycoprotein belonging to the serine protease family. Human FAP is selectively expressed by tumor stromal fibroblasts in epithelial carcinomas, but not by epithelial carcinoma cells, normal fibroblasts, or other normal tissues. FAP has been shown to have both in vitro dipeptidyl peptidase and collagenase activity, but its biological function in the tumor microenvironment is unknown. The modeled structure of murine FAP consists of a short cytoplasmic tail, a single hydrophobic transmembrane region, and a large extracellular domain. A seven-bladed ß-propeller domain is situated on top of the catalytic triad and may serve as a "gate" to selectively filter protein access to the catalytic site. HEK293 cells transfected to constitutively express murine FAP, when xenografted into scid mice, were 2–4 times more likely to develop s.c. tumors and showed a 10–40-fold enhancement of tumor growth compared with mock-transfected HEK293 cells. Rabbits immunized with recombinant murine FAP developed polyclonal anti-FAP antibodies that significantly inhibited murine FAP dipeptidyl peptidase activity in vitro. HT-29 xenografts treated with these inhibitory anti-FAP antisera exhibited attenuated growth compared with tumors treated with preimmunization rabbit antisera. These data demonstrate the ability of FAP to potentiate tumor growth in an animal model. Moreover, tumor growth is attenuated by antibodies that inhibit the proteolytic activity of FAP. These findings suggest a possible therapeutic role for functional inhibition of FAP activity.
This article has been cited by other articles:
|
|
 |
|
  A. M. LeBeau, W. N. Brennen, S. Aggarwal, and S. R. Denmeade Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin Mol. Cancer Ther., May 1, 2009; 8(5): 1378 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Kang, R. Schiff, L. Ko, T. Wang, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley Dual Roles for Coactivator Activator and its Counterbalancing Isoform Coactivator Modulator in Human Kidney Cell Tumorigenesis Cancer Res., October 1, 2008; 68(19): 7887 - 7896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-B. Maes, V. Dubois, I. Brandt, A.-M. Lambeir, P. Van der Veken, K. Augustyns, J. D. Cheng, X. Chen, S. Scharpe, and I. De Meester Dipeptidyl peptidase 8/9-like activity in human leukocytes J. Leukoc. Biol., May 1, 2007; 81(5): 1252 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Henry, H.-O. Lee, J. S. Lee, A. Klein-Szanto, P. Watts, E. A. Ross, W.-T. Chen, and J. D. Cheng Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1736 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chen, A. Kennedy, J.-Y. Wang, W. Zeng, Q. Zhao, M. Pearl, M. Zhang, Z. Suo, J. M. Nesland, Y. Qiao, et al. Activation of EDTA-Resistant Gelatinases in Malignant Human Tumors. Cancer Res., October 15, 2006; 66(20): 9977 - 9985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. Edosada, C. Quan, C. Wiesmann, T. Tran, D. Sutherlin, M. Reynolds, J. M. Elliott, H. Raab, W. Fairbrother, and B. B. Wolf Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity J. Biol. Chem., March 17, 2006; 281(11): 7437 - 7444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Castiglioni, E Tagliabue, M Campiglio, S M Pupa, A Balsari, and S Menard Role of exon-16-deleted HER2 in breast carcinomas. Endocr. Relat. Cancer, March 1, 2006; 13(1): 221 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Aertgeerts, I. Levin, L. Shi, G. P. Snell, A. Jennings, G. S. Prasad, Y. Zhang, M. L. Kraus, S. Salakian, V. Sridhar, et al. Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein {alpha} J. Biol. Chem., May 20, 2005; 280(20): 19441 - 19444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Cheng, M. Valianou, A. A. Canutescu, E. K. Jaffe, H.-O. Lee, H. Wang, J. H. Lai, W. W. Bachovchin, and L. M. Weiner Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth Mol. Cancer Ther., March 1, 2005; 4(3): 351 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Ho, H. Vu, S. A. N. Brown, P. J. Donohue, H. N. Hanscom, and J. A. Winkles Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Overexpression in HEK293 Cells Promotes Tumor Growth and Angiogenesis in Athymic Nude Mice Cancer Res., December 15, 2004; 64(24): 8968 - 8972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Adams, G. T. Miller, M. I. Jesson, T. Watanabe, B. Jones, and B. P. Wallner PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism Cancer Res., August 1, 2004; 64(15): 5471 - 5480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, S. Wang, and T. Kelly Seprase Promotes Rapid Tumor Growth and Increased Microvessel Density in a Mouse Model of Human Breast Cancer Cancer Res., April 15, 2004; 64(8): 2712 - 2716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Kessler, N. Shraga-Heled, T. Lange, N. Gutmann-Raviv, E. Sabo, L. Baruch, M. Machluf, and G. Neufeld Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis Cancer Res., February 1, 2004; 64(3): 1008 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Mikheev, S. A. Mikheeva, B. Liu, P. Cohen, and H. Zarbl A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation Carcinogenesis, January 1, 2004; 25(1): 47 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Cheng and L. M. Weiner Tumors and Their Microenvironments: Tilling the Soil: Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clin. Cancer Res., May 1, 2003; 9(5): 1590 - 1595. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Scott, G. Wiseman, S. Welt, A. Adjei, F.-T. Lee, W. Hopkins, C. R. Divgi, L. H. Hanson, P. Mitchell, D. N. Gansen, et al. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1639 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Engel, T. Hoffmann, L. Wagner, M. Wermann, U. Heiser, R. Kiefersauer, R. Huber, W. Bode, H.-U. Demuth, and H. Brandstetter The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism PNAS, April 29, 2003; 100(9): 5063 - 5068. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
